EU Approves Humira Biosimilar Cyltezo for Treatment of Chronic Inflammatory Diseases

EU Approves Humira Biosimilar Cyltezo for Treatment of Chronic Inflammatory Diseases
The European Commission recently approved Cyltezo, a biosimilar to Humira (adalimumab), for the treatment of chronic inflammatory diseases in adults and children including inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis (UC). Cyltezo developer Boehringer Ingelheim noted that the announcement follows the therapy’s clearance by the U.S. Food and Drug Administration (FDA) in August

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *